Novo Nordisk Aims for U.S. Approval for Tresiba

Jan. 31 (Bloomberg) -- Bloomberg's Caroline Hyde reports that Novo Nordisk A/S stuck to its target of getting U.S. approval for the diabetes treatment Tresiba in the first half as it’s counting on the product to reach higher 2013 forecasts. She speaks on Bloomberg Television's "The Pulse."

China Outlook: Long-Term Plays for Investors
30:52 - Xavier Denis, global strategist at Societe Generale Private Banking, discusses, the inclusion of the yuan in the IMF's SDR basket and what it says about China's economic reforms. He speaks to Bloomberg's Angie Lau on "First Up." (Source: Bloomberg)
  • Cyber Monday: Bloomberg West (Full Show 11/30)
  • China November Manufacturing PMI Below Expectations
  • Stocks Losing Steam?: What'd You Miss? (Full Show 11/30)